Perspectives on the Impact of Varicella Immunization on Herpes Zoster. A Model-Based Evaluation from Three European Countries

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Poletti, Piero ^a,b   Melegaro, Alessia ^b   Ajelli, Marco ^a   del Fava, Emanuele ^c   Guzzetta, Giorgio ^a   Faustini, Luca ^d   Scalia Tomba, Giampaolo ^e   Lopalco, Pierluigi ^f   Rizzo, Caterina ^g   Merler, Stefano ^a   Manfredi, Piero ^h  

^a FONDAZIONE BRUNO KESSLER   (Italy)

^b BOCCONI UNIVERSITY   (Italy)

^c HASSELT UNIVERSITY   (Belgium)

^d ISTAT Regional Office for Tuscany   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^g ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^h UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE;

AGE DISTRIBUTION; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DEMOGRAPHY; EUROPE; FINLAND; HERPES ZOSTER; HUMAN; INCIDENCE; ITALY; MASS IMMUNIZATION; MATHEMATICAL MODEL; SEROPREVALENCE; UNITED KINGDOM; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHICKENPOX; CHILD; CHILD, PRESCHOOL; EVALUATION STUDIES AS TOPIC; FINLAND; GREAT BRITAIN; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNIZATION; INCIDENCE; INFANT; INFANT, NEWBORN; ITALY; MIDDLE AGED; MODELS, BIOLOGICAL; SEROEPIDEMIOLOGIC STUDIES; VACCINATION; YOUNG ADULT;

HERPES ZOSTER; HUMAN HERPESVIRUS 3;

EID: 84876244926     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060732     Document Type: Article

References (60)

1. Nardone A, de Oryb F, Carton M, Cohen D, van Damme P, et al. (2007) The comparative seroepidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 25(45): 7866-7872.
2. Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F, (2011) Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis 52(3): 332-340.
3. Gialloreti LE, Merito M, Pezzotti P, Naldi L, Gatti A, et al. (2010) Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: A retrospective, population-based study. BMC Infect Dis 10: 230.
4. Bilcke J, Ogunjimi B, Marais C, DE Smet F, Callens M, et al. (2012) The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect 140(11): 2096-2109.
5. Hope-Simpson RE, (1965) The nature of herpes zoster: a long-term study and a new hypothesis. P Roy Soc Med 58(1): 9-20.
6. Oxman MN, (2009) Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc 109(6): S13-S17.
7. Asano Y (1996) Varicella vaccine: the Japanese experience. J Infect Dis (Suppl 3): S310-S313.
8. Levin MJ, Barber D, Goldblatt E, Jones M, La Fleur B, et al. (1998) Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis (Suppl 1): S109-S112.
9. Hata A, Kuniyoshi M, Ohkusa Y, (2011) Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection 39(6): 537-44.
10. Gaillat J, Gajdos V, Launay O, Malvy D, Demoures B, et al. (2011) Does Monastic Life Predispose to the Risk of Saint Anthony's Fire (Herpes Zoster)? Clin Infect Dis 53(5): 405-410.
11. Thomas SL, Wheeler JG, Hall AJ, (2002) Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 360(9334): 678-682.
12. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ, (2002) Exposure to varicella boost immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 20(19-20): 2500-2507.
13. Ogunjimi B, Smits E, Hens N, Hens A, Lenders K, et al. (2011) Exploring the Impact of Exposure to Primary Varicella in Children on Varicella-Zoster Virus Immunity of Parents. Viral Immunology 24(2): 151-157.
14. Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, et al. (2001) The post marketing safety profile of varicella vaccine. Vaccine 19(7-8): 916-923.
15. Marin M, Meissner HC, Seward JF, (2008) Varicella prevention in the United States: a review of successes and challenges. Pediatrics 122(3): e744-e751.
16. Nguyen HQ, Jumaan AO, Seward JF, (2005) Decline in mortality due to varicella after implementation of varicella vaccination in the United States. New Engl J Med 352: 450-458.
17. Seward JF, Marin M, Vazquez M (2008) Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis (Suppl 2): S82-S89.
18. Guris D, Jumaan AO, Mascola L, Watson BM, Zhang JX, et al. (2008) Changing varicella epidemiology in active surveillance sites- United States, 1995-2005. J Infect Dis (Suppl 2): S71-S75.
19. Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, et al. (2002) Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. J Am Med Assoc 287(5): 606-611.
20. Shapiro ED, Vazquez M, Esposito D, Holabird N, Steinberg SP, et al. (2011) Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis 203(3): 312-315.
21. Alfonsi V, D'Ancona F, Giambi C, Nacca G, Rota MC, (2011) Regional Coordinators for Infectious Diseases and Vaccinations: Current immunization policies for pneumococcal, meningococcal C, varicella and rotavirus vaccinations in Italy. Health Policy 103(2-3): 176-83.
22. Ramet J, (2007) A new challenge for Europe: introducing a pediatric quadrivalent vaccine for measles, mumps, rubella, and varicella. Int J Infect Dis 11(Suppl 2): S49-55.
23. van Hoek AJ, Melegaro A, Zagheni E, Edmunds WJ, Gay N, (2011) Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England. Vaccine 29(13): 2411-2420.
24. van Hoek AJ, Melegaro A, Gay N, Bilcke J, Edmunds WJ, (2012) The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine 30(6): 1225-1234.
25. Brisson M, Melkonyan G, Drolet M, De Serres G, Thibeault R, et al. (2010) Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster. Vaccine 28(19): 3385-3397.
26. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G, (2000) Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunization programmes. Vaccine 18(25): 2775-2778.
27. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G, (2000) Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 125(3): 651-669.
28. Karhunen M, Leino T, Salo H, Davidkin I, Kilpi T, et al. (2010) Modelling the impact of varicella vaccination on varicella and zoster. Epidemiol Infect 138(4): 469-481.
29. Lu P, Euler GL, Jumaan AO, Harpaz R, (2009) Herpes zoster vaccination among adults aged 60yearsor older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine 27(6): 882-887.
30. Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF (2008) The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J Infect Dis (Suppl 2): S224-S227.
31. Statistical Office of the European Commission (Eurostat). Database by themes. Available: http://epp.eurostat.ec.europa.eu. Accessed 2013 March 6.
32. Schuette MC, Hethcote HW, (1999) Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull Math Biol 61(6): 1031-1064.
33. Heyman DL (2008) Chickenpox/Herpes Zoster. In: Heyman DL, editors. Control of Communicable Diseases Manual. 19 ed.: Washington DC: American Public Health Association 109-116 p.
34. Wallinga J, Teunis P, Kretschmar M, (2006) Using social contact data to estimate age-specific transmission parameters for infectious respiratory spread agents. Am J Epidemiol 164(10): 936-944.
35. Heininger U, Seward JF, (2006) Varicella. Lancet 368(9544): 1365-76.
36. Benenson AS (1995) Control of communicable disease manual. Washington: American Public Health Association.
37. Michalik DE, Steinberg SP, LaRussa PS, Edwards KM, Wright PF, et al. (2008) Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis 197(7): 944-949.
38. Chaves SS, Gargiullo P, Zhang JX, Civen R, Guris D, et al. (2007) Loss of vaccine-induced immunity to varicella over time. New Engl J Med 356: 1121-1129.
39. Black S, Ray P, Shinefield H, Saddier P, Nikas A (2008) Lack of association between age at varicella vaccination and risk of breakthrough varicella, within the Northern California Kaiser Permanente Medical Care Program. J Infect Dis (Suppl 2): S139-S142.
40. Larussa P, Steinberg SP, Shapiro E, Vazquez M, Gershon AA, (2000) Viral strain identification in varicella vaccinees with disseminated rashes. Pediatr Infect Dis J 19(11): 1037-1039.
41. Hambleton S, Steinberg SP, LaRussa PS, Shapiro ED, Gershon AA (2008) Risk of herpes zoster in adults immunized with varicella vaccine. J Infect Dis (Suppl 2): S196-S199.
42. Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, et al. (2001) The effectiveness of the varicella vaccine in clinical practice. New Engl J Med 344: 955-960.
43. Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO, (2004) Contagiousness of varicella in vaccinated cases: A Household Contact Study. J Am Med Assoc 292(6): 704-708.
44. Civen R, Chaves SS, Jumaan A, Wu H, Mascola L, et al. (2009) The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J 28(11): 954-959.
45. Fumanelli L, Ajelli M, Manfredi P, Vespignani A, Merler S, (2012) Inferring the Structure of Social Contacts from Demographic Data in the Analysis of Infectious Diseases Spread. PLoS Comput Biol 8(9): e1002673.
46. Iozzi F, Trusiano F, Chinazzi M, Billari F, Zagheni E, et al. (2010) Little Italy: An Agent-Based Approach to the Estimation of Contact Patterns-Fitting Predicted Matrices to Serological Data. PLoS Comput Bio 6(12): e1001021.
47. Zagheni E, Billari FC, Manfredi P, Melegaro A, Mosssong J, et al. (2008) Using Time-Use Data to Parameterize Models for the Spread of Close-Contact Infectious Diseases. Am J Epidemiol 168(9): 1082-1090.
48. Goeyvarts N, Hens N, Ogunjimi B, Aerts M, Shkedy Z, et al. (2010) Estimating infectious disease parameters from data on social contacts and serological status. Appl Statist 59(2): 255-277.
49. Melegaro A, Jit M, Gay N, Zagheni E, Edmunds WJ, (2011) What types of contacts are important for the spread of infections? Using contact survey data to explore European mixing patterns. Epidemics 3(3-4): 143-151.
50. Asano Y, Nagai T, Miyata T, Yazaki T, Ito S, et al. (1985) Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. Pediatrics 75(4): 667-671.
51. Asano Y, Suga S, Yoshikawa T, Kobayashi I, Yazaki T, et al. (1994) Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 94(4): 524-526.
52. Amanna IJ, Carlson NE, Slifka MK, (2007) Duration of humoral immunity to common viral and vaccine antigens. New Engl J Med 357: 1903-1915.
53. Marino S, Hogue IB, Ray CJ, Kirschner D, (2008) A methodology for performing global uncertainty and sensitivity analysis in systems biology. J Theor Biol 254 (1): 178-196.
54. Anderson RM, May RM (1992) Infectious diseases of humans: dynamics and control. Oxford, UK: Oxford University Press.
55. Kretzschmar M, Teunis PFM, Pebody RG, (2010) Incidence and Reproduction Numbers of Pertussis: Estimates from Serological and Social Contact Data in Five European Countries. PLoS Med 7(6): e1000291.
56. de Melker H, Berbers G, Hahne S, Rumke H, van den Hof S, et al. (2006) The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 24(18): 946-3952.
57. Sanford M, Keating GM, (2010) Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drug Aging 27(2): 159-76.
58. Lu P, Euler GL, Harpaz R, (2001) Herpes zoster vaccination among adults aged 60 years and older, in the US, 2008. Am J Prev Med 40(2): e1-e6.
59. d'Onofrio A, Manfredi P, Poletti P, (2011) The impact of vaccine side effects on the natural history of immunization programmes: an imitation-game approach. J Theor Biol 273(1): 63-71.
60. Liu J, Kochin BF, Tekle YI, Galvani AP, (2011) Epidemiological game-theory dynamics of chickenpox vaccination in the USA and Israel. J R Soc Interface 9(66): 68-76.